Search results
The various and opposing effects of ESRD and dialysis can make blood glucose levels fluctuate widely, placing patients at risk of hypoglycemia—and presenting a challenge for nephrologists and internists. In this review, we summarize the available evidence and make practical recommenda-tions for managing diabetes in patients on he-modialysis.
4 mar 2020 · Stable maintenance hemodialysis patients over 18 years of age and on dialysis for more than 3 months with peripheral arterio-venous access and minimum extracorporeal blood flow of 250 mL/min were included in the study.
29 kwi 2024 · 1. Introduction. Blood flow rate (BFR) is a key determinant of dialysis adequacy under the condition of three times per week for 4 h for each hemodialysis (HD) session [Citation 1]. An increased BFR can significantly improve single-pool Kt/V (spKt/V) and may improve survival in maintenance hemodialysis (MHD) patients [Citation 2, Citation 3].
In 43,806 or 80% of diabetic MHD patients, blood hemoglobin was ≥11.0 g/dL. ... studied 137 hemodialysis patients with type 2 diabetes and reported that the cumulative survival was lower in the group with poor glycemic control ... including slowing the rate of progression of microvascular disease and rate of loss of residual renal function ...
A fourth factor related to the increased prevalence of type 2 diabetics among dialysis patients is improved survival of patients with type 2 diabetes 9 because of better blood pressure control and care for coronary artery disease.
5 wrz 2022 · We investigated in detail the glucose and hormonal profiles in 7 patients with type 2 diabetes on hemodialysis (all male, HbA1c 6.8 ± 2.1%, glycated albumin 24.7 ± 10.2%). All participants were attached continuous glucose monitoring (iPro2®).
30 cze 2021 · Abstract. Diabetic kidney disease (DKD) is the most frequent cause of kidney failure (KF). There are large variations in the incidence rates of kidney replacement therapy (KRT). Late referral to nephrology services has been associated with an increased risk of adverse outcomes.
